1 week Ago By ABMN Staff
Vanguard Group Inc. lifted its stake in shares of Ardelyx, Inc. ( NASDAQ:ARDX – Free Report ) by 5.
6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,362,659 shares of the biopharmaceutical company’s stock after purchasing an additional 767,111 shares during the quarter. Vanguard Group Inc.
owned about 0.06% of Ardelyx worth $72,819,000 at the end of the most recent quarter. Several other hedge funds have also recently modified their holdings of the stock.
Fox Run Management L.L.C.
raised its position in Ardelyx by 214.5% during the 4th quarter. Fox Run Management L.
L.C. now owns 41,531 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 28,324 shares during the last quarter.
KLP Kapitalforvaltning AS purchased a new position in Ardelyx during the fourth quarter worth about $254,000. Teacher Retirement System of Texas raised its holdings in Ardelyx by 19.1% during the fourth quarter.
Teacher Retirement System of Texas now owns 69,867 shares of the biopharmaceutical company’s stock worth $354,000 after purchasing an additional 11,191 shares in the last quarter. Intech Investment Management LLC lifted its position in Ardelyx by 62.3% in the fourth quarter.
Intech Investment Management LLC now owns 99,723 shares of the biopharmaceutical company’s stock valued at $506,000 after purchasing an additional 38,295 shares during the period. Finally, Cibc World Markets Corp purchased a new stake in Ardelyx in the 4th quarter valued at approximately $112,000. 58.
92% of the stock is owned by institutional investors and hedge funds. Ardelyx Stock Performance Ardelyx stock opened at $4.25 on Friday.
The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.
58. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -26.
56 and a beta of 0.81. Ardelyx, Inc.
has a fifty-two week low of $4.02 and a fifty-two week high of $9.33.
The stock has a fifty day moving average of $5.24 and a two-hundred day moving average of $5.41.
Insider Transactions at Ardelyx In related news, CEO Michael Raab sold 41,666 shares of Ardelyx stock in a transaction on Friday, April 4th. The shares were sold at an average price of $4.59, for a total transaction of $191,246.
94. Following the transaction, the chief executive officer now owns 1,615,587 shares in the company, valued at approximately $7,415,544.33.
The trade was a 2.51 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link .
Also, Director David M. Mott purchased 199,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was bought at an average price of $4.
99 per share, with a total value of $993,010.00. Following the completion of the acquisition, the director now owns 1,937,765 shares in the company, valued at $9,669,447.
35. This represents a 11.44 % increase in their position.
The disclosure for this purchase can be found here . Insiders sold a total of 158,076 shares of company stock worth $823,804 in the last ninety days. Insiders own 5.
90% of the company’s stock. Analysts Set New Price Targets Several analysts have recently commented on the company. Cantor Fitzgerald raised Ardelyx to a “strong-buy” rating in a report on Tuesday, March 4th.
HC Wainwright reissued a “neutral” rating and issued a $5.50 target price on shares of Ardelyx in a report on Friday, February 21st. Raymond James reaffirmed a “strong-buy” rating and set a $13.
00 price target (down from $15.00) on shares of Ardelyx in a research note on Friday, February 21st. BTIG Research assumed coverage on shares of Ardelyx in a research note on Tuesday, March 4th.
They issued a “buy” rating and a $14.00 price objective for the company. Finally, Piper Sandler upgraded shares of Ardelyx to a “hold” rating in a research report on Wednesday, March 12th.
Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $10.
61. Check Out Our Latest Stock Analysis on Ardelyx About Ardelyx ( Free Report ) Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.
Recommended Stories Want to see what other hedge funds are holding ARDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ardelyx, Inc. ( NASDAQ:ARDX – Free Report ).
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter ..
